YIN HAIFANG (PhD)

Academic qualifications:

1993-1997 BSc Inner Mongolia National University, China
1997-2000 MSC ShenYang Agricultural University，China
2000-2003 PhD China Agricultural University, China

Previous academic positions held:

2004-2005 Postdoctoral Research Assistant, Clinical Science Center (CSC), Medical Research Council (MRC), Imperial College London, School of Medicine, Hammersmith Hospital, UK
2005-2009 Postdoctoral Research Fellow and Team leader, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

Present academic position:

2010-present Professor, Department of Cell Biology, School of Basic Medical Sciences Tianjin Medical University, Tianjin, China

Previous relevant research work:

Development of novel drug delivery systems including tissue-targeting peptide, natural compounds and exosomes (http://talent.tmu.edu.cn/piintro.jsp?id=9)

Publication records:

Section A-Five most representative publications in the recent five years (* *Corresponding Author***)**

1. Gao X, Ran N, Dong X, Zuo B, Yang R, Zhou Q, Moulton HM, Seow Y, **Yin HF***. Anchor peptide captures, targets and loads exosomes of diverse origins for diagnostics and therapy. ***Sci. Transl. Med.*** 2018; 10:eaat0195.
2. Jing R, Zhou X, Zhao J, Wei Y, Zuo B, You A, Rao Q, Gao X, Yang R, Chen L, Lu Z, Zhou Q, Zhang N, **Yin HF** *. Fluorescent peptide highlights micronodules in murine hepatocellular carcinoma models and human *in vitro*. ***Hepatology*** 2018 Feb 5. doi: 10.1002 /hep.29829.
3. Lu Z , Zuo B, Jing R, Gao X, Rao Q, Liu Z, Qi H, **Yin HF** *. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. ***J. Hepatol.*** 2017; 67: 739-748.
4. Han G, Gu B, Cao L，Gao X，Wang Q，Seow Y，Zhang N，Wood M，**Yin HF***. Hexose enhances oligonucleotide delivery and exon-skipping in dystrophin-deficient *mdx* mice. ***Nat. Commun.*** 2016; 7:10981.
5. Rao Q，Zuo B，Lu Z，Gao X，You A，Wu C，Du Z，**Yin HF***. Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and human *in vitro*. ***Hepatology*** 2016; 64(2):456-472.

Section B-Five representative publications beyond the recent five-year period with the latest publication entered first

6. Dong X, Gao X, Dai Y, Ran N, **Yin HF** *. Serum exosomes can restore cellular function *in vitro* and be used for diagnosis in dysferlinopathy. ***Theranostics*** 2018; 8(5):1243-1255.
7. Guo Z, Jing R, Rao Q, Zhang L, Gao Y, Liu F, Wang X, Hui L, **Yin HF***. Immortalized common marmoset (Callithrix jacchus) hepatic progenitor cells possess bipotentiality *in vitro* and *in vivo.* ***Cell Discovery*** 2018; 4:23.
8. Han G，Lin C，Ning H, Gao X，**Yin HF***. Long-term morpholino oligomers in hexose elicits long-lasting therapeutic improvements in *mdx* mice. ***Molecular Therapy - Nucleic Acids*** 2018; 12:478-489.
9. Gao X，Zhao J，Han G，Zhang Y，Dong X，Cao L，Wang Q，Moulton HM, **Yin HF***. Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient *mdx* mice. ***Molecular Therapy*** 2014; 22(7):1333~1341
10. Cao L，Han G，Lin C，Gu B，Gao X，Moulton HM，Seow Y，**Yin HF***. Fructose promotes uptake and activity of oligonucleotides with different chemistries in a context-dependent manner in *mdx* mice. ***Molecular Therapy - Nucleic Acids*** 2016; 5:e329.

Awards:

2006 - 2007 Merit Award, University of Oxford, Oxford, UK
2008 - 2009 Merit Award, University of Oxford, Oxford, UK
2009 - 2011 Fullford Junior Research Fellowship of Somerville College, University of Oxford, UK
2010 Award for New Century Excellent Talents, China
2012 The first level of Tianjin city "131" innovative talents in Engineering, China
2016 Tianjin Municipal Distinguished Professor, China
2016 Tianjin Municipal "131" innovative talent team leader, China

Patents:

Yin HF, Gao X, Zuo B, Ran N, Xue Dong. Peptide and Peptide conjugates. **Chinese Patent** (Authorization ID: ZL 2015 1 0520565.7)

Yin HF, Gao X, Zhao J, Jing R, Zuo B. Hepatocellualr carcinoma-targeting peptide and its application. **Chinese Patent** (Authorization ID: ZL 2015 1 0522717.7)

Funded Projects:

National Key R&D Program of China (2017YFC1001902): Development of new drugs for Duchenne Muscular Dystrophy and evaluation in non-human primate models (2017.7-2020.12, RMB 2,497,000.00)

National Natural Science Foundation of China (81672124): Investigation of novel biological nanoparticles in targeted therapy of dysferlinopathy (2017.1-2020.12, RMB 610,000.00)

Chinese National Basic Research Program (973)(2012CBA01305): Establishment of Monkey models of major human diseases (2012.1-2016.12, RMB 4,320,000.00)

National Natural Science Foundation of China (China-Canada Joint Health Research Initiative Proposal 81361128013): Targeted delivery of antisense-mediated exon skipping therapy in transgenic pig model of DMD (2014.1-2016.12, RMB 1,000,000.00)

National Natural Science Foundation of China (81273420): Investigation of novel biological nanoparticles in targeted therapy for hepatocellular carcinoma (2013.1-2016.12, RMB 650,000.00)

National Natural Science Foundation of China (81071443): Study of new antisense oligonucleotides in Duchenne muscular dystrophy animal models (2011.1-2013.12, RMB 370,000.00)

Action Duchenne: Development of Peptide Nucleic Acid for Duchenne muscular dystrophy (2011.1-2014.12, GBP 180,000)

Ministry of Education of the People's Republic of China (Award for New Century Excellent Talents-NCET-10-0957): Development of targeted delivery for Duchenne muscular dystrophy (2011.1-2013.12, RMB 500,000.00)